Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704

Pharmacogenomics Journal

Volumn 12, Issue 5, 2012, Pages 395-403

  Farrell, J J ^a   Bae, K ^b   Wong, J ^a   Guha, C ^c   Dicker, A P ^d   Elsaleh, H ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

cancer; cytidine deaminase; gemcitabine; pancreatic cancer; pharmacogenomics

Indexed keywords

CYTIDINE DEAMINASE; FLUOROURACIL; GEMCITABINE; GLUTAMINE; LYSINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DRUG INACTIVATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PANCREAS RESECTION; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84866743985     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.22     Document Type: Article

References (26)

1. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
2. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349-4357.
3. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797-1803.
4. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116: 5325-5335.
5. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006; 107: 4871-4879.
6. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320-329.
7. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019-1026.
8. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 2006; 33(6 Suppl 11): S10-S13.
9. Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007; 3: e29.
10. Steemers FJ, Gunderson KL. Illumina, Inc. Pharmacogenomics 2005; 6: 777-782.
11. Fisher RA. On the interpretation of w2 from contingency tables, and the calculation of P. J R Stat Soci 1922; 85: 87-94.
12. Cox D. Regression models and life-tables. J R Stat Soc 1972; 34: 187-202.
13. Agresti A. Categorical Data Analysis. John Wiley and Sons: New York, 2002.
14. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004; 4: 307-314.
15. van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G. Regulation of phosphorylation of deoxycytidine and 20,20-difluorodeoxycytidine (gemcitabine); effects of cytidine 50-triphosphate and uridine 50-triphosphate in relation to chemosensitivity for 20,20-difluorodeoxycytidine. Biochem Pharmacol 1996; 51: 911-918.
16. Eliopoulos N, Cournoyer D, Momparler RL. Drug resistance to 5-aza-20-deoxycytidine, 20,20-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42: 373-378.
17. Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 2005; 93: 35-40.
18. Ganti AKP, Nguyen DA, Grem JL. Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. J Clin Oncol 2006 ASCO Annu Meet Proc Part I 2006; 24(No. 18S (June 20 Suppl)): 2007.
19. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12: 1794-1803.
20. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26: 421-425.
21. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13: 29-38.
22. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620-2624.
23. Ueno HO, Saijo NT. Association of genetic polymorphisms with survival in Japanese patients treated with gemctiabine (abstract). Eur J Cancer Suppl 2007; 5: 92.
24. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.
25. Mercier C, Evrard A, Ciccolini J. Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. J Clin Oncol 2007; 25: 4855; author reply 4855-6.
26. Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007; 17: 841-844.